Literature DB >> 20495147

NFATc3 contributes to intermittent hypoxia-induced arterial remodeling in mice.

Sergio de Frutos1, Elizabeth Caldwell, Carlos H Nitta, Nancy L Kanagy, Jian Wang, Wei Wang, Mary K Walker, Laura V Gonzalez Bosc.   

Abstract

Sleep apnea (SA) is defined as intermittent respiratory arrest during sleep and affects up to 20% of the adult population. SA is also associated with an increased incidence of hypertension and peripheral vascular disease. Exposing rodents to intermittent hypoxia during sleep mimics the cyclical hypoxia/normoxia of SA. We have previously shown that in mice and rats intermittent hypoxia induces ET-1 upregulation and systemic hypertension. Furthermore, intermittent hypoxia (IH) in mice increases nuclear factor of activated T cells isoform 3 (NFATc3) transcriptional activity in aorta and mesenteric arteries, whereas the calcineurin/NFAT inhibitor cyclosporin A prevents IH-induced hypertension. More importantly, NFATc3 knockout (KO) mice do not develop IH-induced hypertension. The goals of this study were to determine the role of NFATc3 in IH-induced arterial remodeling and whether IH-induced NFATc3 activation is mediated by ET-1. Oral administration of both a dual (bosentan) and a selective endothelin receptor type A antagonist (PD155080) during 2 days of IH exposure attenuated NFAT activation in aorta and mesenteric arteries. Rho kinase inhibition with fasudil also prevented IH-induced NFAT activation. Mesenteric artery cross-sectional wall thickness was increased by IH in wild-type (WT) and vehicle-treated mice but not in bosentan-treated and NFATc3 KO mice. The arterial remodeling in mesenteric arteries after IH was characterized by increased expression of the hypertrophic NFATc3 target smooth muscle-alpha-actin in WT but not in KO mice. These results indicate that ET-1 is an upstream activator of NFATc3 during intermittent hypoxia, contributing to the resultant hypertension and increased wall thickness.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20495147      PMCID: PMC2930384          DOI: 10.1152/ajpheart.00341.2010

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  45 in total

Review 1.  Invited review: Physiological and pathophysiological responses to intermittent hypoxia.

Authors:  J A Neubauer
Journal:  J Appl Physiol (1985)       Date:  2001-04

2.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

3.  Opposing actions of inositol 1,4,5-trisphosphate and ryanodine receptors on nuclear factor of activated T-cells regulation in smooth muscle.

Authors:  Maria F Gomez; Andra S Stevenson; Adrian D Bonev; David C Hill-Eubanks; Mark T Nelson
Journal:  J Biol Chem       Date:  2002-07-26       Impact factor: 5.157

4.  An activated renin-angiotensin system maintains normal blood pressure in aryl hydrocarbon receptor heterozygous mice but not in null mice.

Authors:  Nan Zhang; Larry N Agbor; Jason A Scott; Tyler Zalobowski; Khalid M Elased; Alicia Trujillo; Melissa Skelton Duke; Valerie Wolf; Mary T Walsh; Jerry L Born; Linda A Felton; Jian Wang; Wei Wang; Nancy L Kanagy; Mary K Walker
Journal:  Biochem Pharmacol       Date:  2010-03-30       Impact factor: 5.858

5.  Role of endothelin in intermittent hypoxia-induced hypertension.

Authors:  N L Kanagy; B R Walker; L D Nelin
Journal:  Hypertension       Date:  2001-02       Impact factor: 10.190

Review 6.  Intermittent hypoxia: cell to system.

Authors:  N R Prabhakar; R D Fields; T Baker; E C Fletcher
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2001-09       Impact factor: 5.464

7.  Proteomic analysis reveals alterations in the renal kallikrein pathway during hypoxia-induced hypertension.

Authors:  Visith Thongboonkerd; Evelyne Gozal; Leroy R Sachleben; John M Arthur; William M Pierce; Jian Cai; Julie Chao; Michael Bader; Joao B Pesquero; David Gozal; Jon B Klein
Journal:  J Biol Chem       Date:  2002-07-16       Impact factor: 5.157

Review 8.  Smooth muscle contraction by small GTPase Rho.

Authors:  Yoji Kawano; Takeshi Yoshimura; Kozo Kaibuchi
Journal:  Nagoya J Med Sci       Date:  2002-05       Impact factor: 1.131

9.  A potential role for nuclear factor of activated T-cells in receptor tyrosine kinase and G-protein-coupled receptor agonist-induced cell proliferation.

Authors:  Chandrahasa R Yellaturu; Salil K Ghosh; R K Rao; Lisa K Jennings; Aviv Hassid; Gadiparthi N Rao
Journal:  Biochem J       Date:  2002-11-15       Impact factor: 3.857

10.  Mechanism of RhoA/Rho kinase activation in endothelin-1- induced contraction in rabbit basilar artery.

Authors:  Liyan Miao; Yun Dai; John Zhang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-09       Impact factor: 4.733

View more
  16 in total

1.  Amniotic fluid RNA gene expression profiling provides insights into the phenotype of Turner syndrome.

Authors:  Lauren J Massingham; Kirby L Johnson; Thomas M Scholl; Donna K Slonim; Heather C Wick; Diana W Bianchi
Journal:  Hum Genet       Date:  2014-05-22       Impact factor: 4.132

Review 2.  Targeting the ROS-HIF-1-endothelin axis as a therapeutic approach for the treatment of obstructive sleep apnea-related cardiovascular complications.

Authors:  Elise Belaidi; Jessica Morand; Emmanuelle Gras; Jean-Louis Pépin; Diane Godin-Ribuot
Journal:  Pharmacol Ther       Date:  2016-08-02       Impact factor: 12.310

3.  NFAT regulation of cystathionine γ-lyase expression in endothelial cells is impaired in rats exposed to intermittent hypoxia.

Authors:  Laura V Gonzalez Bosc; Jessica M Osmond; Wieslawa K Giermakowska; Carolyn E Pace; Jennifer L Riggs; Olan Jackson-Weaver; Nancy L Kanagy
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-01-27       Impact factor: 4.733

4.  A dual blocker of endothelin A/B receptors mitigates hypertension but not renal dysfunction in a rat model of chronic kidney disease and sleep apnea.

Authors:  Humberto Morales-Loredo; David Jones; Adelaeda Barrera; Perenkita J Mendiola; Joshua Garcia; Carolyn Pace; Minerva Murphy; Nancy L Kanagy; Laura V Gonzalez Bosc
Journal:  Am J Physiol Renal Physiol       Date:  2019-02-27

5.  The role of the Nox4-derived ROS-mediated RhoA/Rho kinase pathway in rat hypertension induced by chronic intermittent hypoxia.

Authors:  Wen Lu; Jing Kang; Ke Hu; Si Tang; Xiufang Zhou; Lifang Xu; Yuanyuan Li; Shuhui Yu
Journal:  Sleep Breath       Date:  2017-01-11       Impact factor: 2.816

Review 6.  Reactive oxygen species and the brain in sleep apnea.

Authors:  Yang Wang; Shelley X L Zhang; David Gozal
Journal:  Respir Physiol Neurobiol       Date:  2010-09-15       Impact factor: 1.931

7.  AKAP150 contributes to enhanced vascular tone by facilitating large-conductance Ca2+-activated K+ channel remodeling in hyperglycemia and diabetes mellitus.

Authors:  Matthew A Nystoriak; Madeline Nieves-Cintrón; Patrick J Nygren; Simon A Hinke; C Blake Nichols; Chao-Yin Chen; Jose L Puglisi; Leighton T Izu; Donald M Bers; Mark L Dell'acqua; John D Scott; Luis F Santana; Manuel F Navedo
Journal:  Circ Res       Date:  2013-12-09       Impact factor: 17.367

8.  Chronic hypoxia alters fetal cerebrovascular responses to endothelin-1.

Authors:  Jinjutha Silpanisong; Dahlim Kim; James M Williams; Olayemi O Adeoye; Richard B Thorpe; William J Pearce
Journal:  Am J Physiol Cell Physiol       Date:  2017-05-31       Impact factor: 4.249

9.  Intermittent hypoxia-induced increases in reactive oxygen species activate NFATc3 increasing endothelin-1 vasoconstrictor reactivity.

Authors:  J K Friedman; C H Nitta; K M Henderson; S J Codianni; L Sanchez; J M Ramiro-Diaz; T A Howard; W Giermakowska; N L Kanagy; L V Gonzalez Bosc
Journal:  Vascul Pharmacol       Date:  2013-11-15       Impact factor: 5.773

Review 10.  Vasotrophic regulation of age-dependent hypoxic cerebrovascular remodeling.

Authors:  Jinjutha Silpanisong; William J Pearce
Journal:  Curr Vasc Pharmacol       Date:  2013-09       Impact factor: 2.719

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.